Preventing and treating major opportunistic infections in AIDS: What's new and what's still true

Postgraduate Medicine

Volumn 102, Issue 4, 1997, Pages 125-140

  Cavert, Winston ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; BENURYL; CIDOFOVIR; CLARITHROMYCIN; CLINDAMYCIN; CLOTRIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FOLINATE CALCIUM; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; ISONIAZID; MALOPRIM; NYRAZID; NYSTATIN; PENTAMIDINE ISETHIONATE; PRIMAQUINE; PROBENECID; PYRIMETHAMINE; RIFABUTIN; TRIMETHOPRIM; TRIMETREXATE GLUCURONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TOXICITY; CANDIDIASIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DIARRHEA; HERPES VIRUS INFECTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; LUNG TOXICITY; MUSCLE ATROPHY; MYCOBACTERIOSIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; RASH; TUBERCULOSIS;

EID: 0030723322     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.10.332     Document Type: Conference Paper

References (32)

1. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR 1997;46(8):165-73
2. Program and abstracts: 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1997 Jan 22-6;65-224
3. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993;329(26):1922-6
4. Su TH, Martin WJ 2d. Pathogenesis and host response in Pneumocystis carinii pneumonia. Annu Rev Med 1994;45:261-72
5. Telzak EE, Cote RJ, Gold JW, et al. Extrapulmonary Pneumocystis carinii infections. Rev Infect Dis 1990;12(3):380-6
6. Lane HC, Laughon BE, Falloon J, et al. NIH conference: recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994;120(11):945-55 [Erratum, Ann Intern Med 1995;122(4):317]
7. National Institutes of Health - University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990;323(21):1500-4
8. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21 Suppl 1:S32-43
9. Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327(26): 1836-41
10. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sultamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20(4): 849-53
11. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108(4):585-94
12. Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection: causes, response to therapy, and long-term outcome. Ann Intern Med 1995;123(2):143-9
13. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326(4):213-20 [Erratum, N Engl J Med 1992;326(17):1172]
14. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996; 114(1):23-33
15. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112(12):1531-9
16. Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334(23):1491-7
17. Hardy WD. Lessons learned from HIV pathogenesis and therapy: implications for better management of cytomegalovirus disease. AIDS 1996;10 Suppl 1:S31-5
18. Havlik JA Jr, Horsburgh CR Jr, Metchock B, et al. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;165(3):577-80
19. Canadian HIV Trials Network Protocol 010 Study Group. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clotazimine, and ciprofloxacin. N Engl J Med 1996;335(6):377-83
20. AIDS Clinical Trials Group Protocol 157 Study Team. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121(12):905-11
21. Chaisson RE, Keiser P, Pierce M, et al. Controlled trial of clarithromycin/ethambutol with or without clofazimine for Mycobacterium avium bacteremia in AIDS. Abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: 1996 Jan
22. California Collaborative Treatment Group. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335(6): 392-8
23. Centers for Disease Control and Prevention. Tuberculosis morbidity: United States, 1995. MMWR 1996;45(18):365-70
24. American Thoracic Society and the Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149(5):1359-74
25. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337(5):315-20
26. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19(4):684-6
27. Stewart JA, Reef SE, Pellett PE, et al. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21 Suppl 1:S114-20
28. Krown SE. Acquired immunodeficiency syndrome-associated Kaposi's sarcoma: biology and management. Med Clin North Am 1997;81(2):471-94
29. Smith PD. Infectious diarrheas in patients with AIDS. Gastroenterol Clin North Am 1993;22(3):535-48
30. Mannheimer SB, Soave R. Protozoal infections in patients with AIDS: cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am 1994;8(2):483-98
31. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327(5):329-37
32. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333(2):83-8